US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nexalin Technology, Inc.

1.79

-0.0300-1.65%

Volume:55.04K

Turnover:101.41K

Market Cap:23.81M

PE:-2.17

High:1.92

Open:1.85

Low:1.74

Close:1.82

Loading ...

Overview Company News Filings

BRIEF-Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design

Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials

Nexalin Technology Inc - Q-Submission to Facilitate Dialogue With FDA on Clinical Trial Design

THOMSON REUTERS

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 Sync Following Encouraging Data and Preliminary FDA Feedback

THOMSON REUTERS

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia

Nexalin Technology Receives Irb Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

THOMSON REUTERS

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

BRIEF-Nexalin Technology Inc May Offer, Sell Up To $50 Mln Of Common Stock From Time To Time In One Or More Offerings

Nexalin Technology files $50M common stock offering

Nexalin Technology Inc: May Offer, Sell up to $50 Mln of Common Stock From Time to Time in One or More Offerings

THOMSON REUTERS

Nexalin Secures Patent for Intracranial Stimulation Technology

MT Newswires Live

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

The Fallen: Stocks hitting 52-week lows (and what investors should do)

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in Ucsd Clinical Trial

THOMSON REUTERS

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

Nexalin Technology Raised to Buy From Hold by Maxim Group

Nuix Limited's (ASX:NXL) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Simply Wall St.

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NXL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NXL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXL\",,,,,undefined,":{"symbol":"NXL","market":"US","secType":"STK","nameCN":"Nexalin Technology, Inc.","latestPrice":1.79,"timestamp":1746129600000,"preClose":1.82,"halted":0,"volume":55043,"delay":0,"floatShares":10812253,"shares":13303523,"eps":-0.825452,"marketStatus":"Post-Mkt","change":-0.03,"latestTime":"05-01 16:01:25 EDT","open":1.85,"high":1.92,"low":1.7436,"amount":101407.5777,"amplitude":0.096923,"askPrice":1.96,"askSize":10,"bidPrice":1.77,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-0.825452,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746144000000},"marketStatusCode":4,"adr":0,"listingDate":1663300800000,"exchange":"NASDAQ","adjPreClose":1.82,"volumeRatio":1.593389},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXL\",,,,,undefined,":{"symbol":"NXL","floatShares":10812253,"roa":"-123.41%","roe":"-221.05%","lyrEps":-0.825452,"volumeRatio":1.593389,"shares":13303523,"dividePrice":0,"high":1.92,"amplitude":0.096923,"preClose":1.82,"low":1.7436,"week52Low":0.53,"pbRate":"6.48","psRate":"141.14","week52High":4.4899,"institutionHeld":0,"latestPrice":1.79,"committee":0.333333,"eps":-0.825452,"divideRate":0,"volume":55043,"delay":0,"ttmEps":-0.825452,"open":1.85,"prevYearClose":2.76,"prevWeekClose":1.83,"prevMonthClose":1.82,"prevQuarterClose":1.95,"fiveDayClose":1.85,"twentyDayClose":2.01,"sixtyDayClose":3.11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NXL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532000413","title":"BRIEF-Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000413?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:26","pubTimestamp":1746116794,"startTime":"0","endTime":"0","summary":"BRIEF-Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial DesignMay 1 (Reuters) - Nexalin Technology Inc NXL.O:NEXALIN TECHNOLOGY INITIATES FDA Q-SUBMISSION PROCESS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUABNDGG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXL","NXLIW","BK4082"],"gpt_icon":0},{"id":"2532001319","title":"Nexalin Technology Inc. Advances Gen-2 SYNC System with FDA Q-Submission for Alzheimer's and Dementia Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2532001319","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532001319?lang=en_us&edition=fundamental","pubTime":"2025-05-01 22:30","pubTimestamp":1746109814,"startTime":"0","endTime":"0","summary":"Nexalin Technology, Inc.  has announced its intention to initiate a Q-Submission to the U.S. Food and Drug Administration  related to its Gen-2 SYNC system. This regulatory process aims to facilitate dialogue with the FDA regarding the clinical trial design for treating Alzheimer's disease, dementia, and mild cognitive impairment . The company's decision follows encouraging internal data and preliminary feedback from the FDA. Nexalin's Gen-2 SYNC system, featuring technical enhancements and a proprietary 15 milliamp advanced waveform, is positioned as a promising non-invasive therapeutic option for cognitive conditions. The company views this regulatory milestone as a critical step towards advancing its neuromodulation platform for cognitive and neuropsychiatric disorders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL1XlRyH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ","NXL","IE00BKPKM429.USD","BK4082","BK4112","LU2095319765.USD","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2532462006","title":"Nexalin Technology Inc - Q-Submission to Facilitate Dialogue With FDA on Clinical Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2532462006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532462006?lang=en_us&edition=fundamental","pubTime":"2025-05-01 22:30","pubTimestamp":1746109801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUABNDGG2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXL","BK4082"],"gpt_icon":0},{"id":"2532006464","title":"Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 Sync Following Encouraging Data and Preliminary FDA Feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2532006464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532006464?lang=en_us&edition=fundamental","pubTime":"2025-05-01 22:30","pubTimestamp":1746109801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUABNDGG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXL","NXLIW","BK4082"],"gpt_icon":0},{"id":"2532006075","title":"Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2532006075","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532006075?lang=en_us&edition=fundamental","pubTime":"2025-05-01 22:30","pubTimestamp":1746109800,"startTime":"0","endTime":"0","summary":"Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indications. HOUSTON, TX, May 01, 2025  -- Nexalin Technology, Inc.  , today announced that it plans to submit a Q-Submission  to the U.S. Food and Drug Administration  related to its Gen-2 SYNC system. This regulatory milestone is intended to facilitate structured dialogue with the FDA regarding clinical trial design for the treatment of Alzheimer’s disease, dementia, and mild cognitive impairment .Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-initiates-fda-q-143000222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GEN","BK4097","BK4585","LU2286300806.USD","BK4588","BK4082","MCI","NXL","NXLIW"],"gpt_icon":0},{"id":"2529980998","title":"BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529980998","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529980998?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:05","pubTimestamp":1745499909,"startTime":"0","endTime":"0","summary":"BRIEF-Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And InsomniaApril 24  - Nexalin Technology Inc NXL.O:NEXALIN TECHNOLOGY RECEIVES IRB APPROVAL IN BRAZIL AND  BEGINS CLINICAL TRIAL FOR ANXIETY AND INSOMNIASource text: ID:nGNEh93Further company coverage: NXL.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R236I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXL","BK4082"],"gpt_icon":0},{"id":"2529877379","title":"Nexalin Technology Receives Irb Approval in Brazil and  Begins Clinical Trial for Anxiety and Insomnia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529877379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529877379?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:00","pubTimestamp":1745499602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA8ZBQVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXLIW","NXL"],"gpt_icon":0},{"id":"2529980941","title":"Nexalin Technology Receives IRB Approval in Brazil and  Begins Clinical Trial for Anxiety and Insomnia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529980941","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529980941?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:00","pubTimestamp":1745499600,"startTime":"0","endTime":"0","summary":"HOUSTON, TX, April 24, 2025  -- Nexalin Technology, Inc.   the leader in Deep Intracranial Frequency Stimulation  of the brain, today announced that its proprietary Gen-2 neurostimulation device has received institutional review board  approval in Brazil for a new clinical trial evaluating its use in the treatment of anxiety disorders and chronic insomnia. The study will be conducted at the Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de So Paulo , one of Latin America’s most prestigious psychiatric research institutions.The first Nexalin device has been shipped to So Paulo, Brazil, with additional units and single-use disposable electrodes scheduled for delivery in the coming days. These shipments support the launch of a Phase II clinical trial in adult patients suffering from anxiety and insomnia—two conditions that are frequently comorbid and significantly affect quality of life.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-receives-irb-approval-130000945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","NXLIW","NXL"],"gpt_icon":0},{"id":"2529661094","title":"BRIEF-Nexalin Technology Inc May Offer, Sell Up To $50 Mln Of Common Stock From Time To Time In One Or More Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=2529661094","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529661094?lang=en_us&edition=fundamental","pubTime":"2025-04-24 05:58","pubTimestamp":1745445524,"startTime":"0","endTime":"0","summary":"BRIEF-Nexalin Technology Inc May Offer, Sell Up To $50 Mln Of Common Stock From Time To Time In One Or More OfferingsApril 23  - Nexalin Technology Inc NXL.O:NEXALIN TECHNOLOGY INC: MAY OFFER, SELL UP TO $50 MILLION OF COMMON STOCK FROM TIME TO TIME IN ONE OR MORE OFFERINGSSource text: [ID:n0001829126-25-002877]Further company coverage: NXL.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R123A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2529866153","title":"Nexalin Technology files $50M common stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2529866153","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529866153?lang=en_us&edition=fundamental","pubTime":"2025-04-24 05:35","pubTimestamp":1745444145,"startTime":"0","endTime":"0","summary":"17:30 EDT Nexalin Technology (NXL) files $50M common stock offering Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nexalin-technology-files-50m-common-stock-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nexalin-technology-files-50m-common-stock-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2529669744","title":"Nexalin Technology Inc: May Offer, Sell up to $50 Mln of Common Stock From Time to Time in One or More Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=2529669744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529669744?lang=en_us&edition=fundamental","pubTime":"2025-04-24 05:29","pubTimestamp":1745443768,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R123A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2527842115","title":"Nexalin Secures Patent for Intracranial Stimulation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2527842115","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527842115?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:59","pubTimestamp":1744649949,"startTime":"0","endTime":"0","summary":"Nexalin Technology  said Monday it secured a patent for its deep intracranial frequency stimulation technology in treating substance use disorders.The firm said the US Patent and Trademark Office granted its patent \"Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder and Substance Use Disorder.\"The technology may help regulate neural pathways linked to addiction and withdrawal symptoms, offering an alternative treatment pathway, Nexalin said.Price: 1.97, Change: +0.08, Percent Change: +4.23","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","BK4082","NXL","NXL.AU"],"gpt_icon":0},{"id":"2527115583","title":"Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2527115583","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527115583?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:30","pubTimestamp":1744648200,"startTime":"0","endTime":"0","summary":"Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment. HOUSTON, TX, April 14, 2025  -- Nexalin Technology, Inc.   the leader in Deep Intracranial Frequency Stimulation  of the brain, is pleased to announce that the United States Patent and Trademark Office  has officially granted its patent titled \"Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder  and Substance Use Disorder .\". This milestone further strengthens Nexalin’s intellectual property portfolio and affirms the potential of its proprietary Deep Intracranial Frequency Stimulation  technology, a non-invasive and drug-free solution designed to aid individuals struggling with substance use disorders , including opioid use disorder , alcohol use disorder , and stimulant addiction such as cocaine and methamphetamine dependence. By applying non-invasive deep-brain stimulation at dynamic frequencies, DIFS technology may help regulate neural pathways lin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-secures-uspto-patent-163000456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","NXLIW","MAT","NXL","BK4190"],"gpt_icon":0},{"id":"2526364374","title":"The Fallen: Stocks hitting 52-week lows (and what investors should do)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526364374","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526364374?lang=en_us&edition=fundamental","pubTime":"2025-04-10 10:48","pubTimestamp":1744253281,"startTime":"0","endTime":"0","summary":"Earlier this week, I covered The Outlaws – stocks hitting 52-week highs despite the market sinking.The Outlaw Stocks: The ASX names defying the sell-off and hitting 52-week highs. Unlike in 2022, when almost every asset class fell in lockstep, this year we’ve seen defensives and fixed income ETFs do what they’re meant to do: offer ballast in a storm.Now, let's flip the script and look at the stocks and ETFs which hit 52-week lows before today's bigger-than-Ben-Hur rally. We'll call them:The Fallen.To be sure, these aren’t necessarily all bad businesses. As fund managers like Emanuel Datt, Adam Dawes, and Nick Peros have pointed out, a stock hitting a 52-week low isn’t always a red flag.It's a potential opportunity to pick up quality at a discount.Due to the sheer number of names hitting 52-week low, we’ve  focused this wire on two key ASX sectors – resources and financials – with expert insights to help investors make sense of the wreckage.You can download the full list below or use th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-fallen-stocks-hitting-52-week-lows-and-what-investors-should-do","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-fallen-stocks-hitting-52-week-lows-and-what-investors-should-do","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["NDQ.AU","BK7016","LU2089283258.USD","CSL.AU","LU0795875169.SGD","BK4516","LU0795875086.SGD","TNE.AU","BK4585","MQG.AU","LU2028103732.USD","XRO.AU","LU0158827948.USD","LU1548497426.USD","LU2237443978.SGD","LU0170899867.USD","REA.AU","LU2023251221.USD","LU2471134523.USD","IE00B19Z3B42.SGD","BHP.AU","LU0225283273.USD","MIN.AU","NXL","LU1162221912.USD","RMD","LU0251131958.USD","BK7507","LU0742534661.SGD","PNI.AU","BK7002","GQG.AU","LU2471134796.USD","LU2237438978.USD","BK4127","RIO.AU","LU1732800096.USD","BK4552","MFG.AU","LU2089284900.SGD","LU0314104364.USD","BK4550","LU2237443549.SGD","LU0912757837.SGD","LU1868837136.USD","RMD.AU","NXL.AU","BK7508","LU2471134879.HKD","LU2008162690.USD"],"gpt_icon":0},{"id":"2524985504","title":"Nexalin Technology Enrolls First Patients and Advances Toward Treatment in Ucsd Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524985504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524985504?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:30","pubTimestamp":1743597031,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2524493820","title":"Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524493820","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524493820?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:30","pubTimestamp":1743597000,"startTime":"0","endTime":"0","summary":"HOUSTON, TX, April 02, 2025  -- Nexalin Technology, Inc.   the leader in Deep Intracranial Frequency Stimulation  of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego , in collaboration with the VA San Diego Healthcare System . The company began treatment of the first patients this week with the Nexalin HALO.The trial follows the recent successful shipment and integration of Nexalin’s HALO Clarity devices at UCSD, where they are being used to provide non-invasive, at-home neurostimulation therapy with AI-integrated remote monitoring. Nexalin’s Electronic Data Capture  platform and Patient Monitoring System  enable real-time tracking of patient adherence and treatment progress. As the study progresses, additional HALO Clarity devices will be deployed to ensure optimal patient coverage and data collection.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-enrolls-first-patients-123000694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NXL","NXLIW","BK4082","EDC"],"gpt_icon":0},{"id":"2522808581","title":"Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522808581","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522808581?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:30","pubTimestamp":1742992200,"startTime":"0","endTime":"0","summary":"Houston, TX, March 26, 2025  -- Nexalin Technology, Inc.   is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET.This press release contains statements that constitute \"forward-looking statements,\" These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact  should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended Dece","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-nexalin-technology-exclusive-live-123000933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NXL","NXLIW"],"gpt_icon":0},{"id":"2521747056","title":"Nexalin Technology Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747056","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747056?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:10","pubTimestamp":1742818200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NXL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 08:10 ET (12:10 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXL"],"gpt_icon":0},{"id":"2519404368","title":"Nuix Limited's (ASX:NXL) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio","url":"https://stock-news.laohu8.com/highlight/detail?id=2519404368","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519404368?lang=en_us&edition=fundamental","pubTime":"2025-03-15 05:56","pubTimestamp":1741989417,"startTime":"0","endTime":"0","summary":"Unfortunately for some shareholders, the Nuix Limited ( ASX:NXL ) share price has dived 29% in the last thirty days...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-nxl/nuix-shares/news/nuix-limiteds-asxnxl-29-dip-still-leaving-some-shareholders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NXL","BK4082","BK7016","NXL.AU"],"gpt_icon":0},{"id":"2519801176","title":"Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2519801176","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519801176?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:00","pubTimestamp":1741957200,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc.  and Calidi Biotherapeutics, Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nexalin-technology-calidi-biotherapeutics-interviews-130000894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4100","TM","BK4581","TV","ET","BK4187","BK4555","NXLIW","BK4099","CLDI","BK4585","BK4590","BK4604","AIRI","NXL","03160","BK4561","BK4144","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NXL\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NXL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NXL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1742875200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NXL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NXL","date":"2025-04-30","current":-3.182836,"percent":0.438486,"low":-11.123806,"twenty":-5.073412,"median":-2.952867,"eighty":-1.217582,"high":-0.46259,"avg":-3.375975,"sd":2.478432,"marketCap":24212411},"quantilePoints":[{"date":"2022-09-16","current":-5.073734,"twenty":-6.382342,"median":-6.382342,"eighty":-5.597177,"marketCap":16379912},{"date":"2022-09-23","current":-2.773641,"twenty":-5.858899,"median":-3.709464,"eighty":-3.008161,"marketCap":8954352},{"date":"2022-09-30","current":-2.435392,"twenty":-4.568616,"median":-2.908941,"eighty":-2.579712,"marketCap":7862357},{"date":"2022-10-07","current":-2.503042,"twenty":-3.729758,"median":-2.593242,"eighty":-2.489512,"marketCap":8080756},{"date":"2022-10-14","current":-2.886391,"twenty":-3.427589,"median":-2.773641,"eighty":-2.503042,"marketCap":9318350},{"date":"2022-10-21","current":-3.044241,"twenty":-3.11189,"median":-2.852566,"eighty":-2.512062,"marketCap":9827947},{"date":"2022-10-28","current":-3.333782,"twenty":-3.13895,"median":-2.908715,"eighty":-2.525592,"marketCap":10762694},{"date":"2022-11-04","current":-3.630539,"twenty":-3.342712,"median":-2.948628,"eighty":-2.543632,"marketCap":11720737},{"date":"2022-11-11","current":-8.471203,"twenty":-3.677893,"median":-2.954041,"eighty":-2.579712,"marketCap":13249529},{"date":"2022-11-18","current":-8.378112,"twenty":-4.631756,"median":-3.015602,"eighty":-2.593242,"marketCap":13103929},{"date":"2022-11-25","current":-10.658821,"twenty":-7.755915,"median":-3.13444,"eighty":-2.629322,"marketCap":16671110},{"date":"2022-12-02","current":-10.938092,"twenty":-8.471203,"median":-3.31484,"eighty":-2.782661,"marketCap":17107908},{"date":"2022-12-09","current":-10.333006,"twenty":-9.802392,"median":-3.467052,"eighty":-2.818741,"marketCap":16161513},{"date":"2022-12-16","current":-3.444335,"twenty":-9.802392,"median":-3.607989,"eighty":-2.818741,"marketCap":5387171},{"date":"2022-12-23","current":-3.63517,"twenty":-9.44865,"median":-3.619264,"eighty":-2.832271,"marketCap":5685649},{"date":"2022-12-30","current":-3.486225,"twenty":-9.076288,"median":-3.596714,"eighty":-2.886391,"marketCap":5452690},{"date":"2023-01-06","current":-3.504843,"twenty":-8.852872,"median":-3.596714,"eighty":-2.90425,"marketCap":5481810},{"date":"2023-01-13","current":-4.326829,"twenty":-8.648074,"median":-3.630539,"eighty":-2.908896,"marketCap":6767451},{"date":"2023-01-20","current":-5.301949,"twenty":-8.527057,"median":-3.653322,"eighty":-2.929642,"marketCap":8292603},{"date":"2023-01-27","current":-5.205601,"twenty":-8.471203,"median":-3.704665,"eighty":-2.949666,"marketCap":8141908},{"date":"2023-02-03","current":-5.026867,"twenty":-8.415348,"median":-3.810938,"eighty":-2.953951,"marketCap":7862357},{"date":"2023-02-10","current":-5.678498,"twenty":-8.378112,"median":-3.923688,"eighty":-2.954041,"marketCap":8881552},{"date":"2023-02-17","current":-5.119958,"twenty":-8.21083,"median":-4.305419,"eighty":-2.967571,"marketCap":8007957},{"date":"2023-02-24","current":-4.087122,"twenty":-7.763997,"median":-4.305419,"eighty":-2.98074,"marketCap":6392533},{"date":"2023-03-03","current":-4.468326,"twenty":-6.909555,"median":-4.267252,"eighty":-3.009875,"marketCap":6988762},{"date":"2023-03-10","current":-4.747597,"twenty":-6.382342,"median":-4.328691,"eighty":-3.071301,"marketCap":7425560},{"date":"2023-03-17","current":-5.026867,"twenty":-6.100804,"median":-4.480661,"eighty":-3.12993,"marketCap":7862357},{"date":"2023-03-24","current":-4.794607,"twenty":-5.641262,"median":-4.519061,"eighty":-3.175481,"marketCap":7499087},{"date":"2023-03-31","current":-3.433381,"twenty":-5.576099,"median":-4.480661,"eighty":-3.247866,"marketCap":5829249},{"date":"2023-04-06","current":-3.31965,"twenty":-5.510936,"median":-4.366393,"eighty":-3.315802,"marketCap":5636155},{"date":"2023-04-14","current":-3.60505,"twenty":-5.306138,"median":-4.305419,"eighty":-3.315802,"marketCap":6120712},{"date":"2023-04-21","current":-3.347546,"twenty":-5.306138,"median":-4.128082,"eighty":-3.315802,"marketCap":5683518},{"date":"2023-04-28","current":-3.562562,"twenty":-5.306138,"median":-4.003341,"eighty":-3.322476,"marketCap":6048575},{"date":"2023-05-05","current":-3.733802,"twenty":-5.3053,"median":-3.915598,"eighty":-3.335677,"marketCap":6339308},{"date":"2023-05-12","current":-3.01616,"twenty":-5.282679,"median":-3.810938,"eighty":-3.335677,"marketCap":6192120},{"date":"2023-05-19","current":-2.818112,"twenty":-5.188472,"median":-3.732836,"eighty":-3.214916,"marketCap":5785530},{"date":"2023-05-26","current":-2.767002,"twenty":-5.119958,"median":-3.715347,"eighty":-3.089151,"marketCap":5680603},{"date":"2023-06-02","current":-3.273482,"twenty":-5.119958,"median":-3.699867,"eighty":-3.044241,"marketCap":6720396},{"date":"2023-06-09","current":-3.251121,"twenty":-5.119958,"median":-3.681736,"eighty":-3.052363,"marketCap":6674490},{"date":"2023-06-16","current":-3.263544,"twenty":-5.073734,"median":-3.647538,"eighty":-3.044241,"marketCap":6699993},{"date":"2023-06-23","current":-3.023969,"twenty":-5.073476,"median":-3.630539,"eighty":-3.042316,"marketCap":6208150},{"date":"2023-06-30","current":-3.229471,"twenty":-5.073412,"median":-3.607989,"eighty":-3.049114,"marketCap":6630042},{"date":"2023-07-07","current":-3.28271,"twenty":-5.073412,"median":-3.60505,"eighty":-3.06656,"marketCap":6739341},{"date":"2023-07-14","current":-2.838342,"twenty":-5.054794,"median":-3.60505,"eighty":-3.038466,"marketCap":5827063},{"date":"2023-07-21","current":-2.875965,"twenty":-5.026867,"median":-3.603763,"eighty":-3.000615,"marketCap":5904301},{"date":"2023-07-28","current":-2.789363,"twenty":-5.008249,"median":-3.588807,"eighty":-2.957877,"marketCap":5726509},{"date":"2023-08-04","current":-2.594508,"twenty":-4.961704,"median":-3.5728,"eighty":-2.942778,"marketCap":5326476},{"date":"2023-08-11","current":-2.284658,"twenty":-4.933777,"median":-3.560201,"eighty":-2.908805,"marketCap":4690359},{"date":"2023-08-18","current":-1.816454,"twenty":-4.933777,"median":-3.537425,"eighty":-2.875326,"marketCap":4424754},{"date":"2023-08-25","current":-1.282203,"twenty":-4.933777,"median":-3.497652,"eighty":-2.827127,"marketCap":3123356},{"date":"2023-09-01","current":-1.360051,"twenty":-4.915159,"median":-3.486225,"eighty":-2.818364,"marketCap":3312988},{"date":"2023-09-08","current":-1.283424,"twenty":-4.887232,"median":-3.444801,"eighty":-2.803631,"marketCap":3126330},{"date":"2023-09-15","current":-1.312732,"twenty":-4.887232,"median":-3.433381,"eighty":-2.788795,"marketCap":3197721},{"date":"2023-09-22","current":-1.312732,"twenty":-4.887139,"median":-3.39261,"eighty":-2.768493,"marketCap":3197721},{"date":"2023-09-29","current":-1.472702,"twenty":-4.877551,"median":-3.360231,"eighty":-2.700987,"marketCap":3587397},{"date":"2023-10-06","current":-1.190617,"twenty":-4.840687,"median":-3.343255,"eighty":-2.636674,"marketCap":2900259},{"date":"2023-10-13","current":-1.330438,"twenty":-4.831471,"median":-3.336304,"eighty":-2.575202,"marketCap":3240853},{"date":"2023-10-20","current":-1.010498,"twenty":-4.785205,"median":-3.31965,"eighty":-2.503042,"marketCap":2461502},{"date":"2023-10-27","current":-1.037974,"twenty":-4.766401,"median":-3.31484,"eighty":-2.480492,"marketCap":2528431},{"date":"2023-11-03","current":-0.924102,"twenty":-4.747597,"median":-3.278273,"eighty":-2.375098,"marketCap":2251047},{"date":"2023-11-10","current":-1.098726,"twenty":-4.736426,"median":-3.263544,"eighty":-1.867376,"marketCap":2676418},{"date":"2023-11-17","current":-0.465824,"twenty":-4.684017,"median":-3.249346,"eighty":-1.703376,"marketCap":2141729},{"date":"2023-11-24","current":-0.526479,"twenty":-4.652366,"median":-3.216344,"eighty":-1.47551,"marketCap":2420600},{"date":"2023-12-01","current":-0.630966,"twenty":-4.633097,"median":-3.194333,"eighty":-1.433259,"marketCap":2901002},{"date":"2023-12-08","current":-0.64714,"twenty":-4.607776,"median":-3.192381,"eighty":-1.383558,"marketCap":2975368},{"date":"2023-12-15","current":-0.622393,"twenty":-4.601166,"median":-3.165229,"eighty":-1.337643,"marketCap":2861589},{"date":"2023-12-22","current":-0.483617,"twenty":-4.588878,"median":-3.140169,"eighty":-1.312732,"marketCap":2223532},{"date":"2023-12-29","current":-0.650213,"twenty":-4.584689,"median":-3.123348,"eighty":-1.283424,"marketCap":2989497},{"date":"2024-01-05","current":-0.630804,"twenty":-4.5602,"median":-3.103112,"eighty":-1.276097,"marketCap":2900259},{"date":"2024-01-12","current":-0.750495,"twenty":-4.528986,"median":-3.052363,"eighty":-1.223467,"marketCap":3450564},{"date":"2024-01-19","current":-0.727851,"twenty":-4.517385,"median":-3.034616,"eighty":-1.19715,"marketCap":3346452},{"date":"2024-01-26","current":-0.528905,"twenty":-4.506122,"median":-3.016515,"eighty":-1.180419,"marketCap":2431755},{"date":"2024-02-02","current":-0.627407,"twenty":-4.483128,"median":-2.986964,"eighty":-1.132613,"marketCap":2884642},{"date":"2024-02-09","current":-0.490248,"twenty":-4.442634,"median":-2.958836,"eighty":-1.026617,"marketCap":2254021},{"date":"2024-02-16","current":-0.514672,"twenty":-4.373933,"median":-2.953815,"eighty":-0.975085,"marketCap":2366314},{"date":"2024-02-23","current":-0.501408,"twenty":-4.328319,"median":-2.942336,"eighty":-0.95921,"marketCap":2305334},{"date":"2024-03-01","current":-0.501733,"twenty":-4.322547,"median":-2.909667,"eighty":-0.893084,"marketCap":2306828},{"date":"2024-03-08","current":-0.881508,"twenty":-4.290152,"median":-2.892646,"eighty":-0.76764,"marketCap":4052926},{"date":"2024-03-15","current":-0.873421,"twenty":-4.211677,"median":-2.875432,"eighty":-0.727851,"marketCap":4015743},{"date":"2024-03-22","current":-0.721381,"twenty":-4.136461,"median":-2.838342,"eighty":-0.725133,"marketCap":3316706},{"date":"2024-03-28","current":-1.261608,"twenty":-4.114119,"median":-2.824855,"eighty":-0.727851,"marketCap":5800518},{"date":"2024-04-05","current":-3.439365,"twenty":-4.114119,"median":-2.834438,"eighty":-0.727851,"marketCap":15988608},{"date":"2024-04-12","current":-3.935274,"twenty":-4.087122,"median":-2.8749,"eighty":-0.727851,"marketCap":18293942},{"date":"2024-04-19","current":-2.351566,"twenty":-4.003341,"median":-2.866559,"eighty":-0.748716,"marketCap":10931746},{"date":"2024-04-26","current":-2.215591,"twenty":-3.983265,"median":-2.830534,"eighty":-0.750495,"marketCap":10299638},{"date":"2024-05-03","current":-2.639513,"twenty":-3.968788,"median":-2.818741,"eighty":-0.761817,"marketCap":12270327},{"date":"2024-05-10","current":-1.855657,"twenty":-3.967268,"median":-2.818112,"eighty":-0.782844,"marketCap":8626411},{"date":"2024-05-17","current":-2.001563,"twenty":-3.952607,"median":-2.803737,"eighty":-0.792549,"marketCap":9890627},{"date":"2024-05-24","current":-1.595231,"twenty":-3.935274,"median":-2.80356,"eighty":-0.808723,"marketCap":7882755},{"date":"2024-05-31","current":-1.090175,"twenty":-3.909679,"median":-2.788653,"eighty":-0.830719,"marketCap":5387045},{"date":"2024-06-07","current":-1.120273,"twenty":-3.883526,"median":-2.768954,"eighty":-0.840101,"marketCap":5535776},{"date":"2024-06-14","current":-2.077261,"twenty":-3.85501,"median":-2.767712,"eighty":-0.860481,"marketCap":10264686},{"date":"2024-06-21","current":-1.655428,"twenty":-3.830253,"median":-2.724235,"eighty":-0.876656,"marketCap":8180218},{"date":"2024-06-28","current":-4.454606,"twenty":-3.84715,"median":-2.724235,"eighty":-0.879891,"marketCap":22012223},{"date":"2024-07-05","current":-2.106908,"twenty":-3.825734,"median":-2.700469,"eighty":-0.883801,"marketCap":10411186},{"date":"2024-07-12","current":-2.977935,"twenty":-3.813241,"median":-2.733284,"eighty":-0.907828,"marketCap":14715321},{"date":"2024-07-15","current":-3.042207,"twenty":-3.81209,"median":-2.748489,"eighty":-0.915327,"marketCap":15032918},{"date":"2024-08-02","current":-2.442335,"twenty":-3.810938,"median":-2.733284,"eighty":-0.922826,"marketCap":12068680},{"date":"2024-08-09","current":-1.943584,"twenty":-3.75526,"median":-2.700469,"eighty":-0.922826,"marketCap":9604129},{"date":"2024-08-16","current":-1.920801,"twenty":-3.733802,"median":-2.661944,"eighty":-0.924102,"marketCap":10379065},{"date":"2024-08-23","current":-1.871233,"twenty":-3.73187,"median":-2.637596,"eighty":-0.925323,"marketCap":10111225},{"date":"2024-08-30","current":-1.841452,"twenty":-3.727312,"median":-2.59952,"eighty":-0.946388,"marketCap":9950299},{"date":"2024-09-06","current":-1.664538,"twenty":-3.724719,"median":-2.593242,"eighty":-0.956646,"marketCap":8994343},{"date":"2024-09-13","current":-1.449613,"twenty":-3.717092,"median":-2.557016,"eighty":-0.95921,"marketCap":7832997},{"date":"2024-09-20","current":-1.372421,"twenty":-3.71064,"median":-2.525592,"eighty":-0.966048,"marketCap":7415886},{"date":"2024-09-27","current":-1.313449,"twenty":-3.701786,"median":-2.500617,"eighty":-0.972643,"marketCap":7097231},{"date":"2024-10-04","current":-1.234297,"twenty":-3.692337,"median":-2.480492,"eighty":-0.976306,"marketCap":6669534},{"date":"2024-10-11","current":-1.246052,"twenty":-3.689082,"median":-2.453466,"eighty":-0.988395,"marketCap":6733053},{"date":"2024-10-18","current":-2.586146,"twenty":-3.677534,"median":-2.447548,"eighty":-0.992859,"marketCap":13974261},{"date":"2024-10-25","current":-4.212284,"twenty":-3.677534,"median":-2.463268,"eighty":-1.000905,"marketCap":22761108},{"date":"2024-10-31","current":-4.46698,"twenty":-3.703705,"median":-2.480017,"eighty":-1.007426,"marketCap":24137361},{"date":"2024-11-08","current":-6.661286,"twenty":-3.729135,"median":-2.498191,"eighty":-1.013427,"marketCap":35994310},{"date":"2024-11-15","current":-7.814261,"twenty":-3.813241,"median":-2.514317,"eighty":-1.017579,"marketCap":43404904},{"date":"2024-11-22","current":-9.030439,"twenty":-3.916078,"median":-2.543339,"eighty":-1.026146,"marketCap":50160259},{"date":"2024-11-29","current":-9.678778,"twenty":-3.96818,"median":-2.586146,"eighty":-1.033718,"marketCap":53761508},{"date":"2024-12-06","current":-9.655623,"twenty":-4.10332,"median":-2.593875,"eighty":-1.044166,"marketCap":53632892},{"date":"2024-12-13","current":-9.632468,"twenty":-4.274885,"median":-2.607519,"eighty":-1.059474,"marketCap":53504276},{"date":"2024-12-20","current":-7.085421,"twenty":-4.373933,"median":-2.640081,"eighty":-1.074524,"marketCap":39356511},{"date":"2024-12-27","current":-6.668632,"twenty":-4.468057,"median":-2.668127,"eighty":-1.083553,"marketCap":37041422},{"date":"2025-01-03","current":-7.432746,"twenty":-4.514872,"median":-2.696993,"eighty":-1.083553,"marketCap":41285752},{"date":"2025-01-10","current":-6.877026,"twenty":-4.585982,"median":-2.709344,"eighty":-1.088851,"marketCap":38198966},{"date":"2025-01-17","current":-7.316971,"twenty":-4.61634,"median":-2.763695,"eighty":-1.097016,"marketCap":40642671},{"date":"2025-01-24","current":-6.020293,"twenty":-4.736426,"median":-2.768422,"eighty":-1.108068,"marketCap":33440173},{"date":"2025-01-31","current":-6.668632,"twenty":-4.840687,"median":-2.771387,"eighty":-1.114296,"marketCap":37041422},{"date":"2025-02-07","current":-8.52103,"twenty":-4.887232,"median":-2.789363,"eighty":-1.117882,"marketCap":47330706},{"date":"2025-02-14","current":-7.432746,"twenty":-4.933777,"median":-2.80356,"eighty":-1.129754,"marketCap":41285752},{"date":"2025-02-21","current":-7.502211,"twenty":-5.026867,"median":-2.805689,"eighty":-1.14568,"marketCap":41671600},{"date":"2025-02-28","current":-6.251842,"twenty":-5.073605,"median":-2.818741,"eighty":-1.160332,"marketCap":34726333},{"date":"2025-03-07","current":-5.302488,"twenty":-5.119958,"median":-2.821798,"eighty":-1.164363,"marketCap":29453075},{"date":"2025-03-14","current":-4.515219,"twenty":-5.171344,"median":-2.838342,"eighty":-1.171933,"marketCap":25080129},{"date":"2025-03-21","current":-4.337051,"twenty":-5.119958,"median":-2.875432,"eighty":-1.180419,"marketCap":32992737},{"date":"2025-03-28","current":-3.60255,"twenty":-5.119958,"median":-2.892646,"eighty":-1.189335,"marketCap":27405257},{"date":"2025-04-04","current":-3.165348,"twenty":-5.117381,"median":-2.908828,"eighty":-1.190617,"marketCap":24079376},{"date":"2025-04-11","current":-3.060419,"twenty":-5.097603,"median":-2.908941,"eighty":-1.190983,"marketCap":23281165},{"date":"2025-04-17","current":-2.903026,"twenty":-5.07367,"median":-2.910392,"eighty":-1.194342,"marketCap":22083848},{"date":"2025-04-25","current":-3.2353,"twenty":-5.073412,"median":-2.942889,"eighty":-1.208577,"marketCap":24611517},{"date":"2025-04-30","current":-3.182836,"twenty":-5.073412,"median":-2.952867,"eighty":-1.217582,"marketCap":24212411}],"updateTime":1746127439077}}}